Jennifer L Mitchell

US Patent:

20110046064, Feb 24, 2011

Filed:

May 1, 2009

Appl. No.:

12/990487

Inventors:

Howard L. Fields - Berkeley CA, US
Jennifer L. Whistler - Kensington CA, US
Jennifer M. Mitchell - Berkeley CA, US
Elyssa B. Margolis - Berkeley CA, US
Richard M. van Rijn - Berkeley CA, US

Assignee:

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - Oakland CA

International Classification:

A61K 38/08
A61K 31/4375
A61K 31/439
A61K 31/4184
A61P 25/30
A61P 25/36

US Classification:

514 177, 514285, 514279, 514289, 514282, 514394

Abstract:

The present invention provides methods of treating or preventing a substance-related disorder using selective delta opioid receptor-1 (DOP-R1) agonists, delta opioid receptor-2 (DOP-R2) antagonists, and/or mu opioid receptor (MOP-R) antagonists, or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. The methods provided herein further comprise administering a therapeutically effective amount of a combination of a DOP-R1 agonist and a DOP-R2 antagonist. The methods also comprise administering a therapeutically effective amount of a combination of a DOP-R1 agonist and an MOP-R antagonist. The methods provided herein further comprise administering a therapeutically effective amount of a combination of a DOP-R1 agonist and a DOP-R2 antagonist and a MOP-R antagonist. The invention also relates to compositions containing the same. The invention also relates to methods of determining delta opioid receptor specificity of candidate agents.

US Patent:

20060258647, Nov 16, 2006

Filed:

Apr 18, 2006

Appl. No.:

11/406818

Inventors:

Jennifer Mitchell - Berkeley CA, US
Howard Fields - Berkeley CA, US

International Classification:

A61K 31/5513

US Classification:

514221000

Abstract:

The present invention provides a method of mitigating a symptom of maladaptive substance use in a subject by inhibiting CCKreceptors. In addition, the invention provides a variety of prescreening and screening methods aimed at identifying agents that modulate a symptom of maladaptive substance use. Methods of the invention can involve assaying test agent binding to CCKreceptors. Alternatively, test agents can be screened for their ability to alter the level of CCKreceptor polypeptides, polynucleotides, or function. Finally, the invention also provides a diagnostic method that entails measuring one or more of these levels and determining risk for maladaptive substance use based on comparison to the corresponding level for a control population.